Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with <i>RAS</i>/<i>BRAF</i> Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial

Huabin Hu(Sun Yat-sen University), Yanhong Deng(Sun Yat-sen University), Ping Lan(Sun Yat-sen University), Zehua Wu(Shanghai Jiao Tong University), Rongbo Lin(Fujian Provincial Cancer Hospital), Guangjian Liu(Sun Yat-sen University), Meng Qiu(Northeast Normal University), Jiayu Ling(Sun Yat-sen University), Yue Cai(Sun Yat-sen University), Meijin Huang(Sun Yat-sen University), Huaiming Wang(Sun Yat-sen University), Tenghui Ma(Sun Yat-sen University), Liang Kang(Sun Yat-sen University), Jianwei Zhang(Capital Medical University), Ming Liu(Guizhou Center for Disease Control and Prevention), Kun Wang(Chinese Academy of Sciences), Wei Wang(Central South University), Haibo Zhang(Guangzhou University of Chinese Medicine), Li Ling(Xinjiang Academy of Forestry), Hui Wang(People’s Hospital of Rizhao), Yonghua Cai(Sun Yat-sen University), Xiaojian Wu(Guangxi Academy of Agricultural Science), Jiaming Zhou(Sun Yat-sen University), Shuangling Luo(Sun Yat-sen University), Yunle Wan(Sun Yat-sen University), Yan Huang(Xinxiang Medical University), Zhiyang Zhou(Shanghai Jiao Tong University), Fangqian Li(Central South University)
The Oncologist
September 3, 2020
Cited by 50


Related Papers